正在加载视频...
视频加载失败
SEC filings should be standard evidence in every drug-pricing conversation. Rob Burgess argues policymakers should compare pharma’s public promises with the legally binding disclosures made to investors—before declaring a deal finished.
168,411 次观看 • 2 个月前 •via X (Twitter)
0 条评论
暂无评论
原始帖子的评论将显示在这里


